Mutations in the BRCA1 and BRCA2 genes predispose individuals to the development of breast and ovarian cancers. As a result, biochemical functions of BRCA1 and BRCA2 proteins are being characterised in great detail. These studies have prompted the use of PARP inhibitors to treat BRCA1 and BRCA2-deficient ovarian cancers. This example of synthetic lethality represents a conceptual progress made recently in the approach to cancer treatment and is being currently tested in multiple clinical trials. Other than BRCA1 and BRCA2, many other factors might influence the survival of ovarian cancer patients. Currently, ovarian cancer remains the fifth most common cancer in the United Kingdom among women. Recent evidence suggests benefit in the modulation of the ubiquitin-proteasome system for the treatment of ovarian cancer. In this manuscript, we review the role of Cullin-Ring ubiquitin Ligases (CRLs) in the pathogenesis of ovarian cancer and their potential therapeutic exploitation. CRLs comprise a large family of proteins that, like kinases, might represent ideal candidates for targeted therapy and provide a large repertoire for the development of new anti-cancer compounds.
BRCA1 and BRCA2 are susceptibility loci that predispose individuals to the development of ovarian and breast cancers. The protein product of BRCA1 gene codes for an E3 ubiquitin ligase and BRCA2 acts as a scaffold to favour Rad51 recruitment at single strand DNA. BRCA1 and BRCA2 are both required for the repair of double strand break (DSB) lesions within DNA (Aparicio et al, 2014) . Specifically, these proteins allow the correct execution of Homologous Recombination (HR) in mammalian cells for the efficient repair of DSBs. The loss of BRCA1 and BRCA2 represents a pathogenetic mechanism as it favours genome instability, but it also points to a specific cancer weakness. Indeed, by inducing DSBs in cancer cells that lack BRCA function, it is possible to sensitise specifically these cells and leave normal tissue intact, given the inability of these cancer cells to properly handle DSBs. It was shown that PARP inhibitors sensitise cancer cells-bearing BRCA1 and BRCA2 mutations (Bryant et al, 2005) , through the obligate use of BRCA1/2 for repair of DSBs. This evidence is among the first applied examples of synthetic lethality in cancer therapy. Ovarian cancer patients might benefit from the treatment with PARP inhibitors and numerous clinical trials attempting to confirm these benefits are in progress.
Although several factors besides BRCA1/2 influence success of therapy and cancer cell survival, these might be masked by the profound genetic heterogeneity of cancers. In the following review, we discuss the role of Cullin-Ring ubiquitin Ligases (CRLs) in the pathogenesis of epithelial ovarian cancer and their potential therapeutic exploitation.
CULLIN-RING UBIQUITIN LIGASES ORGANISATION AND CHEMICAL TARGETING
The ubiquitin system is typically organised in multiple layers of specificity. The human genome codes for two E1s, B35 E2s and more than 500 E3 ubiquitin ligases. Cullin proteins assemble the largest class of RING E3 ligases known as CRLs. Nine cullins have been described and Cul1, Cul2, Cul3, Cul4, Cul5, Cul7, Cul9 have been shown to assemble with a diverse family of E3s (Table 1) . The general feature is that cullins bridge together with a ring finger protein (RBX1/2) and an adaptor (Skp1, ElonginC/B, DDB1). The ring finger protein (RBX1/2) recruits the E2 whereas the adaptor recruits the E3. An activated ubiquitin molecule is transferred from the E2 to the substrates through substrate recruitment mediated by the E3. The system allows for the regulation of protein ubiquitination in space and time with high selectivity due to the large number of substrate recognition domains present in the E3s with unique features. A further layer of CRLs control is mediated by the Nedd8, a ubiquitin like molecule that is added to the cullins in order to promote the ubiquitinating activity of the CRLs complexes (Figure 1 ). Neddylation of cullins is catalysed in a manner similar to ubiquitination for which the molecular details have been analysed in a recent elegant study (Scott et al, 2014) .
Modulation of the ubiquitin system is exploited in a number of cancer therapies. Bortezomib (Velcade, http://www.velcade.com/ files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf), a general inhibitor of the proteasome (Adams and Kauffman, 2004) , is used in the treatment of patients with multiple myeloma and mantle cell lymphoma. Novel drugs that target the ubiquitination system have been developed and are currently being tested in clinical trials. For instance, MLN4924, a Nedd8-activating Figure 1 . Cullin-Ring ubiquitin Ligases (CRLs) are prototypical multi-subunit ubiquitin ligases. This figure presents the assembly of a prototypical multi-subunit E3 through adaptors. Substrates contain a degron that serves as a signalling platform for the recruitment by the E3. Rbx1/2 are recruited by cullins to bridge the substrate selected by the substrate recognition protein to the E2. E2 and E1 provide activated ubiquitin molecules that are coupled with target lysine residues within the substrates. Poly-ubiquitinated substrates are degraded by the proteasome. NAE (Nedd8-activating enzyme) catalyses the transfer of Nedd8 to cullins. Chemical approaches to target the CRLs are outlined. enzyme inhibitor, prevents the neddylation of cullins and hampers the activity of all the CRLs (Soucy et al, 2009 ). MLN4924 is being tested in the treatment of haematological malignancies and solid tumours (www.clinicaltrials.gov). In vitro, it was shown that MLN4924 possesses significant cytotoxic activity against both cisplatin-sensitive and -resistant ovarian cancer cells (Nawrocki et al, 2013) . These data suggest that CRLs might represent important targets in ovarian cancer therapy; however, more studies are required to define the contribution of each E3 to the observed effect. Although it was shown that Cul3-dependent ubiquitin ligases mediate the outcome of MLN4924 in ovarian cancer cell lines, it was also suggested that Cul1 siRNA has an opposite effect and increased cisplatin resistance (Jazaeri et al, 2013) . Furthermore, recent data showed that Cul4a could mediate the effect of MLN4924 as it was observed that siRNA targeting the E3 ubiquitin ligase DCAF2/CTD2 induces drug sensitivity similar to that observed with MLN4924 treatment (Pan et al, 2013) . The emerging picture is not clear, but it indicates that a better definition of the biological role of E3 ubiquitin ligases might lead to significant improvements in chemotherapy regimens, as well as the development of new targeted compounds in ovarian cancer. It is worth mentioning that recent evidence suggests that lenalidomide (Revlimid, http://www.revlimid.com/wp-content/uploads/2013/11/ PI.pdf), currently used in the treatment of multiple myelomas, myelodysplastic syndrome and mantle cell lymphomas, exerts its anti-cancer activity by promoting the recognition of IKFZ1 and IKZF3 by the CRL4, Cereblon (Lu et al, 2014) . The discovery that lenalidomide can act as a decoy for E3 ubiquitin ligases opens the possibility to modulate the E3 activity, revealing novel therapeutic routes. Unfortunately, at this moment, the function of many E3 enzymes is poorly characterised and molecular mechanisms of action remain unknown for most of them.
CUL1-DEPENDENT UBIQUITIN LIGASES
Prototypical multi-subunit ubiquitin ligases are the Cul1-dependent E3s. Through Skp1, they recruit the F-box proteins for substrate recognition. 69F-box proteins are present in mammalian cells with multiple roles in cell signalling, proliferation and development. F-box proteins differ notably in their substrate recruitment strategy and function. They are also classified as Fbxw's, Fbxl's and Fbxo's. The Fbxw's contain an F-box domain and a WD-40 motif that mediates the interaction with target substrates through specific serine and threonine phosphorylation consensus sequences. Fbxl's contain leucine-rich repeats and also seem to prefer phosphorylated substrates, while the rest of the F-box protein family (FBXs) lack either WD-40 repeats or leucinerich repeats (Jin et al, 2004) . The Fbxos have a wide range of protein recognition domains, such as a helicase domain in Fbx18, a cyclin domain in Fbxo1 (cyclin F) and many others. For a comprehensive classification, please refer to Jin et al (2004) .
The Fbxw7 is among the most well-characterised Fbxw's and its role in cancer has been extensively studied. Fbxw7 is a tumour suppressor that is frequently mutated in multiple cancer types. Fbxw7 targets the products of several oncogenes for degradation, including cyclin E, NOTCH, JUN and c-Myc (Minella and Clurman, 2005) . Surprisingly enough, mutations in Fbxw7 are not common in serous ovarian cancers. We have analysed the essentiality of each F-box in ovarian cancer cell lines using the DSPC database (http://dpsc.ccbr.utoronto.ca/cancer/), which is a collection of shRNA dropout signature profiles, covering approximately 16 000 human genes derived from more than 70 pancreatic, ovarian and breast cancer human cell lines. We have plotted each F-box according to its cumulative GARP score (derived from the sum of GARP score in individual ovarian cell lines). The GARP score quantifies the shRNA dropout rate of a gene, based on the GARP (Gene Activity Ranking Profile). According to the database, Fbxw7 is required for the survival of the following ovarian cancer cell lines (GARP score is indicated in parenthesis): OVCA1369_TR ( À 2.89); OVCA8( À 0.54); SK-OV3 ( À 0.28); A2780( À 0.28). The latter indicates that Fbxw7 could also act as an oncogene in certain instances and indeed, it was recently reported that Fbxw7 targets p100, a component of the NFkB pathway, for degradation as a pro-survival mechanism in multiple myeloma (Busino et al, 2012) . Although in other cancers cyclin E amplification is mediated by Fbxw7 loss, in ovarian cancer, cyclin E is amplified through locus amplification. Hence, it will be interesting to analyse in more detail the survival requirement of Fbxw7 in ovarian cancer subtypes.
In our analysis, we have plotted the F-boxes with low GARP value (lower GARP value indicates higher growth control) with the total number of mutations in ovarian cancer, derived from the Catalogue Of Somatic Mutations In Cancer (COSMIC) database. Although simplistic, this approach correlates the function of a protein to the presence of mutations (Figure 2) . The presence of mutations might not always predict high significance of a certain gene. Poorly transcribed regions in the ovarian cancer genome might be more mutated simply because transcription-coupled repair is not active in these regions. However, if a particular gene is required for cell growth and this requirement is coupled to the presence of mutations in the gene, this could reflect a functional significance even in the presence of a low mutation rate.
In a recent genome-wide sequencing of ovarian cancers, mutational signatures were clustered in pathways (Cancer genome atlas research network, 2011). According to this analysis, alteration of HR repair is a frequent event. In fact, it has been observed that 20% of high grade serous ovarian cancer (HGS-OvCa) samples contain somatic and germline mutations in BRCA1/2 and 11% have lost BRCA1 expression through DNA hypermethylation. Mutations in other components of HR and
FbxI7
Number of mutations in ovarian cancer (COSMIC) GARP score Figure 2. Analysis of the cumulative GARP score derived from the DPSC-cancer database and number of mutations in ovarian cancer from COSMIC of the indicated F-box proteins. GARP scores are reported as positive values, however GARP score is derived as a negative score. For details, please refer to (http://dpsc.ccbr.utoronto. ca/cancer/). Number of mutations identified in the COSMIC database (ovarian cancer subset) (http://cancer.sanger.ac.uk/cancergenome/ projects/cosmic/)were counted for the F-box proteins scoring in the DPSC database. Please note synonymous mutations have been omitted. F-box proteins not included in the graph did not score in the DPSC.
DNA damage response (ATM/ATR, components of the Fanconi anaemia core complex and Rad51 mutations) can also take place. Considering the summation of all the DNA damage response genes altered, it has been calculated that HR defects might be present in approximately half of all HGS-OvCa cases (Cancer genome atlas research network, 2011). This observation could have a major therapeutic relevance as cancers with HR defects can benefit from PARP inhibitors-based therapy. Our analysis suggests that Fbxo18 has a low GARP score in ovarian cancer cell lines and is mutated with low frequency. Interestingly, it was shown that Fbxo18 modulates HR by disrupting Rad51 recruitment (Simandlova et al, 2013) . On the light of the role of Fbxo18 in HR, we speculate that the mutations reported in Fbxo18 might be relevant for the treatment of ovarian cancer and could modulate the response to PARP inhibitors. Mutations in Fbxo18 were reported in melanoma, where inactivation of Fbxo18 was shown to protect cells from UV-induced DNA damage (Jeong et al, 2013) . Noteworthy, another Fbox -Fbxo44 -has a sugar recognition domain and it was observed that Fbxo44 targets BRCA1 for degradation. Although these findings are interesting, functional significance of the proteolysis of BRCA1 is not yet clear, and it remains unexplained how Fbxo44 mediates BRCA1 for ubiquitination and subsequent degradation through the sugar recognition domain . In the future, the role of Fbxo18 and Fbxo44 in ovarian cancer will need to be more thoroughly investigated. Alteration of cell cycle is another common feature in HGSOvCa. For instance, amplification of cyclin D1 and D2 is present in 5 and 15% of HGS-OvCa, respectively. Fbxo31 was shown to target cyclin D1 for degradation and in our analysis, Fbxo31 is among the F-boxes harbouring mutations and showing essentiality in one cell line (Santra et al, 2009) .
Other cell cycle components significantly altered in HGs-OvCa are RB1, p21, p57 and cyclin E. As RB1 can affect the levels of cyclin F (Fbxo1) (D'Angiolella et al, unpublished observation), we hypothesise that alteration of cyclin F levels might be relevant in ovarian cancer progression and prognosis. We have previously shown that cyclin F targets RRM2, a subunit of ribonucleotide reductase, for degradation during the G2 phase of the cell cycle (D'Angiolella et al, 2012 (D'Angiolella et al, , 2013 . A statistically significant direct association of RRM2 expression levels and the relative risk of death was observed in serous ovarian cancer (Wang et al, 2012) . Moreover, cyclin F is the only F-box together with Fbxl18 that clusters in the survival signature derived from the TCGA analysis of HGS-OvCa (Cancer genome atlas research network, 2011). In light of these observations, it will be interesting to investigate in more detail the roles that cyclin F and RRM2 have in the prognosis and survival of ovarian cancer patients.
Skp2, also known as Fbxl1, acts as an oncogene by targeting p27 for degradation. Regulation of p27 allows cell cycle progression by modulating CDK activity (Carrano et al, 1999) . Numerous human cancers, including ovarian cancers, express low levels of p27 and high levels of Skp2. A study showed that Skp2 À / À mice have specific developmental defects in the ovary (Fotovati et al, 2011) . Thus, blocking Skp2 activity might be beneficial for cancer therapy, especially for ovarian cancer. As a matter of fact, various chemical inhibitors of Skp2 have been developed (Wu et al, 2012; Chan et al, 2013) . However, at this moment, the high IC 50 (half maximal inhibitory concentration) of these compounds and poor pharmacological properties significantly complicate their development for use in the clinic.
Other F-box proteins that have a described role in the proliferation of ovarian cancer cells are Fbxo22 and Fbxo32. Fbxo22 is among the hits of the 106 cell-line screening performed at the Broad Institute. siRNA targeting of Fbxo22 can block specifically the growth of ovarian cancer cell lines (Cheung et al, 2011) . Fbxo22 targets KDM4A for degradation and alteration of Fbxo22 leads to changes in H3K9me3 and H3K36me3 histone marks, as well as changes in transcriptional levels of KDM4A's target gene, ASCL2 (Tan et al, 2011) . The investigation of Fbxo22 in ovarian cancer might reveal novel aspects of epigenetic changes associated with cancer progression. Fbxo32, also known as atrogin, was initially described as an inductor of atrophy, a physiological condition that leads to a reduction in muscle cell size and increased protein catabolism. Fbxo32 is transcriptionally silenced in ovarian cancers and re-expression of Fbxo32 inhibits growth progression of ovarian cancer cells through promotion of apoptosis (Chou et al, 2010) . Other F-box proteins included in our analysis might have relevant roles as well, but their functional roles in ovarian cancer cell lines remain unexplored.
INSIGHTS INTO OTHER CRLS
Among the numerous CRLs, Cul1-dependent machineries are the most thoroughly studied. Although other CRLs might also be relevant in the survival of ovarian cancer cells as described above, it is difficult to establish the relative contribution of each one of them as many of these enzymes are poorly characterised at this moment.
Cullin-Ring ubiquitin Ligases 4 (CRL4s) use the protein DDB1 as an adaptor and recruit substrates via DDB4 and Cul4 associated factors (DCAFs). The function of the majority of DCAFs is unknown, but recent work has demonstrated that the expression of the E3 DCAF2/CDT2 could serve as a biomarker of ovarian cancer prognosis. Inhibition of CDT2 arrests ovarian cell proliferation and might mediate the effect of MLN4924 on overcoming cisplatin resistance (Birner et al, 2012; Pan et al, 2013) .
CRL3s assemble complexes with BTB proteins (B200 in the human genome). Inhibition of Cul3 sensitises ovarian cancer cells to cisplatin. Investigation of BTBs in ovarian cancer might reveal the specific BTB mediating cisplatin sensitivity and provide a novel target for combined therapy. It is important to mention that disruption of the Cul3/Keap/Rbx1 has been reported in serous ovarian cancer (Martinez et al, 2014) , but the significance for platinum-based therapies is unclear.
Given the broad spectrum of the topic, the description of each CRL is outside the scope of this review. Nevertheless, it is easy to envision that given the complexity of CRLs, we will see a large number of discoveries flourish on this interesting class of molecular machineries in the future. We hope that these molecular details will be translated into more effective treatments through the development of compounds that are more specific for the E3 ligases.
CONCLUSION
Exome sequencing of cancers has drastically improved our understanding of the aetiology and pathogenesis of various cancer types. Unfortunately, the low number of cases, high cytogenetic variability and tumour population heterogeneity, as well as the contamination of samples with stromal components, might render this analysis difficult to interpret and highly variable across studies. Also, recent evidence has suggested that alterations contained in the non-coding regions of the genome and silent mutations might significantly contribute to cancer development (Supek et al, 2014) . Thus, although the major cancer drivers can be easily seen in current studies, more functional studies will be necessary to define novel drivers and therapeutical targets. In order to exploit the synthetic lethality principle effectively and develop novel targeted therapies, we will need to aim node components of signalling pathways and increase our understanding about the physiological processes that control cell survival. In addition, we will need to combine several drugs and target multiple pathways to prevent aberrant circuits from developing. Indeed, cancer cells overcome easily the targeting of a single genetic aberration through development of resistance. An accumulating body of evidence suggests strongly that multiple genetic aberrations work independently or together to confer survival ability to cancer cells. In summary, it is only the combination of functional studies and genomic signatures that will allow us to make progress in ovarian cancer treatment. In the future, we will need to learn how diverse pathways interact and integrate them in order to predict the development of drug resistance by cancer cells.
